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We appreciate the observation by Dr. Wallace uncovering our
error in citing unwittingly the nomenclature of amino acid alter-
ation of the mutation g.963G>A (according to the NCBI reference
sequence NM_014585) of SLC40A1 gene, as R178G (Arg178Gly)
instead of R178Q (Arg178Gln). An Erratum has already been sub-
mitted in concern to our initial publication [1]. We have to
emphasize that all the data presented in both our initial publica-
tion describing this alteration and in the Letter to the Editor [2]
are absolutely correct. At the time of the submission of the initial
publication in Blood Cells Molecules and Diseases, this alteration
(R178Q) was really novel, as the paper of Cunat et al. [3] had not
appeared in the literature. Unfortunately, a database of ferropor-
tin gene (SLC40A1) mutations is not yet available. It would be
worthy such a database to be established for SLC40A1, as it is
the rule for other genes of clinical interest. Very usefully, a formal
and detailed review of the incoming alterations is provided by
such databases.
To the end, we have recently performed a detailed bioinfor-
matic analysis in order to assess whether this alteration is likely
to be deleterious and, if possible, to determine which aspects of
protein function are affected. For this purpose, we used two dif-
ferent software packages, namely SIFT (Sorting Intolerant From
Tolerant; available at: http://sift.bii.a-star.edu.sg/) and PolyPhen2
(available at: http://genetics.bwh.harvard.edu.pph2/) and we
determined that the R178Q mutation is rather deleterious for
protein function (intolerant on SIFT analysis with a probability
score 0.00, and probably damaging on PolyPhen2 analysis: sensi-
tivity score 0.00, speciﬁcity score: 1.00), causing the emergence
of the classical ferroportin disease.
We honestly apologize for our mistake. Such mistakes would
be really avoided using the cDNA numbering position rather than
nucleotide positions obtained from NCBI reference sequences
(that are regularly updated) and the presentation of amino acidJournal of Hepatology 201substitutions by both three letter and single letter codes, as it is
rightly proposed by Dr. Wallace.
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